Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Mar 1;13:764854. doi: 10.3389/fphar.2022.764854

Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular Carcinoma

Xueliang Zhou 1,†, Tengfei Zhang 2,†, Yali Sun 3,†, Chunwei Li 4, Xianfei Ding 3, Yanhui Zhu 3, Lifeng Li 4,*, Zhirui Fan 5,*
PMCID: PMC8921872  PMID: 35300300

Abstract

Aim: To explore the relationship between the use of aspirin and the incidence of hepatocellular carcinoma (HCC).

Methods: MEDLINE, EMBASE, Web of Science and Cochrane CENTRAL databases were searched systematically from the earliest available date to 13 March 2020. The primary outcome was incidence of HCC, and the secondary outcomes were recurrence and mortality of HCC. The results were expressed as the Hazard Ratio (HR) and 95% confidence interval (CI). Based on the heterogeneity evaluated with the I 2 statistic, a meta-analysis was performed using either a random- or fixed-effects model.

Results: A total of sixteen articles (2781100 participants) were included. There was lower incidence of HCC in aspirin users than those in non-aspirin users (HR, 0.56; 95% CI, 0.46-0.69; p < 0.001). Subgroup analysis further showed that the incidence of liver cancer in patients with alcoholic cirrhosis (HR, 0.14; 95% CI, 0.09-0.22; p < 0.001) and virus hepatitis (HR, 0.68; 95% CI, 0.62-0.74; p < 0.001) who use aspirin was lower than that of patients who do not use aspirin. In addition, aspirin was found to associate with decreased risk of HCC mortality (HR, 0.71; 95% CI, 0.65-0.78; p < 0.001), not HCC recurrence (HR, 0.52; 95% CI, 0.15-1.76; p = 0.291).

Conclusions: Aspirin use is significantly associated with the low incidence rate of liver cancer.

Keywords: hepatocellular carcinoma, aspirin, HCC, meta-analysis, systematic review 3

1 Introduction

Hepatocellular carcinoma (HCC) accounts for a large proportion of cancer deaths worldwide ((Torre et al., 2015; Bray et al., 2018)), and the incidence of HCC is predicted to increase in the future ((Torre et al., 2015; Bray et al., 2018)). HCC can grow at an exponential rate; its recurrence can occur after a therapy and its subsequent metastasis can lead to mortality, making it the second cause of death of cancer patients ((Torre et al., 2015; Bray et al., 2018)). The current diagnosis of HCC remains ineffective; thus, it is important that preventive methods are developed ((Torre et al., 2015; Bray et al., 2018)). The main risk factors for HCC are chronic hepatitis and virus infection, in particular hepatitis B virus (HBV) and hepatitis C virus (HCV), and long-term drinking ((Chen et al., 1991; Degos et al., 2000; Yeh et al., 2010)). Several studies have suggested that chronic hepatitis inflammation could induce HCC((Raza et al., 2011; Hossain et al., 2012; Li et al., 2013a)), especially occurring through the cyclooxygenase-2 (COX-2) pathway ((Cheng et al., 2004)). Thus, modulation of the inflammatory pathways may become a novel method that can restrict HCC development.

Aspirin is a COX inhibitor frequently used to reduce the risk of cardiovascular and cerebrovascular disease-related death, owing to its antiplatelet effect. Moreover, aspirin has been shown to play a role in preventing lung cancer, colorectal cancer and prostate cancer ((Cao et al., 2016; Lapi et al., 2016; Ye et al., 2019)). It has been also shown to have a beneficial effect in liver, such as lowering the risk of hepatic inflammation, fibrosis, and HCC, according to the data from chronic hepatitis animal model ((Cao et al., 2016; Lapi et al., 2016; Ye et al., 2019)). The mechanisms underlying the chemopreventive effect of aspirin, however, remain unknown. Recent studies have explored the associations between HCC and the chemopreventive effect of aspirin that is associated with chronic inflammation. Beside the inflammatory process ((Sitia et al., 2012; Carrat 2014)), aspirin has been suggested to modulate immune response of liver and promote the liver injury mediated by immune and carcinogenesis ((Semple et al., 2011)). This information demonstrates that aspirin plays roles in pathogenesis of HCC.

Given the evidence of aspirin’s chemopreventive effect, it may potentially be prevent HCC. Recent articles have indicated that due to anti-inflammation and immune modulation effect of aspirin ((Sahasrabuddhe et al., 2012; Petrick et al., 2015; Hwang et al., 2018)), number of HCC incidence in patients taking aspirin is lower compared with that in patients without aspirin. Conversely, several studies have reported that use of aspirin has no notable effect on the incidence of HCC ((Sahasrabuddhe et al., 2012; Petrick et al., 2015; Hwang et al., 2018)). Given such equivocal information, it is necessary to compile and evaluate data from available articles to determine whether aspirin is beneficial for preventing the incidence of HCC.

2 Methods

2.1 Search Strategy

The meta-analysis was performed based on the Meta-analysis of Observational Studies in Epidemiology guidelines and the protocol of this study in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) checklist ((Stroup et al., 2000)). And the PRISMA checklist is shown in Supplementary Table S1. Articles written in English language published from the earliest possible date to 13 March 2020 in the MEDLINE, EMBASE, Web of Science and Cochrane CENTRAL databases and were searched using a combination of MeSH/Emtree and title/abstract keywords. The keywords were “Acetylsalicylic acid,” “Aspirin,” “Hepatocellular Carcinoma,” “Liver cancer,” “Hepatic cellular cancer,” and “HCC”. Supplementary Table S2 showed the detailed search strategy.

2.2 Inclusion and Exclusion Criteria

2.2.1 Incidence

The inclusion criteria of this study are as follows (Torre et al., 2015): they enrolled patients using aspirin and non-aspirin for prevention or treatment (Bray et al., 2018); they counted the HCC incidence of aspirin and non-aspirin users (McGlynn and London 2011); they were adults patients (age ≥18 years) (Altekruse et al., 2012); they were observational studies or clinical trials (Villanueva 2019); they were written in English. The articles were excluded when (Torre et al., 2015): These studies lacked the results of the correlation between the use of aspirin and HCC incidence rate and hazard ratio (HR), relative risk, odd ratio (OR) and 95% confidence interval (CI), or did not provide raw data (Bray et al., 2018).; they were reviews, commentaries, editorials, conference abstracts, or animal studies (McGlynn and London 2011); they assessed the impact of aspirin combined with other NSAIDs on the incidence of HCC.

2.2.2 Recurrence and Mortality

The inclusion criteria of this study are as follows (Torre et al., 2015): they enrolled HCC patients who used aspirin and non-aspirin (Bray et al., 2018); they counted the HCC recurrence, mortality of patients using aspirin and non-aspirin (McGlynn and London 2011); they were adults patients (age ≥18 years) (Altekruse et al., 2012); they were observational studies or clinical trials (Villanueva 2019); they were written in English. The articles were excluded when (Torre et al., 2015): the studies lacked outcome data for correlation between the use of aspirin and HCC recurrence, mortality with hazard ratio (HR), relative risk, or odd ratio(OR) value and 95% confidence interval (CI), or not provide the raw data as we can calculate out the result (Bray et al., 2018); they were reviews, commentaries, editorials, conference abstracts, or animal studies (McGlynn and London 2011); they assessed the effect of aspirin in combination with other NSAIDs on the recurrence, mortality of HCC.

2.3 Inclusion of Studies and Data Extraction

These articles were first extracted based on the inclusion criteria by two investigators; after that, the differences between them were determined by another investigator. The articles that were included into this study contain the following information: first author’s name, year of publication, area where the study was conducted, study design, study period, total number of aspirin/no-aspirin users, HCC number of aspirin/no-aspirin users, liver disease status, primary and secondary outcomes, definition of aspirin user, aspirin dose, adjusted variables. We show these in Table 1 and Table 2. Aspirin users was defined as people who had used aspirin before or after HCC, and the specific information was shown in Table 2. If available, the HR and its related 95% CI were extracted directly from the original article. If not, the HR and 95% CI were calculated according to the raw data in the study. In addition, several case-control studies of this meta-analysis only provide the odd ratio not HR ((Yang et al., 2016; Shen et al., 2020)), so we treated the odd ratio is approximately equivalent to the HR value and then to pooled together because the incidence of HCC is far below 5% (Akinyemiju et al., 2017), namely if research results are rare in all subjects and subgroups, people can usually ignore the differences between various relative risk measures (such as odds ratio, ratio and risk ratio) (Greenland 1987; Siristatidis et al., 2013; Grant 2014).

TABLE 1.

Baseline characteristics for studies included in the meta-analysis.

Study Region Study design Study period Total number of aspirin/no-aspirin users HCC number of aspirin/no-aspirin users Liver disease status Reason for aspirin Primary outcome (HR, 95% CI) Secondary outcome (HR, 95% CI)
Incidence Recurrence Mortality
Jacobs et al. (2012)41 America RC 1997–2018 23869/76270 22/15 NA NA NA NA 0.52 (0.30–0.93)
Sahasrabuddhe et al. (2012)21 America PC 1995–2008 219291/81213 159/90 NA NA 0.59 (0.45–0.77) NA NA
Yeh et al. (2014)44 Taiwan RC 01/1997-12/2010 377/15197 9812/5762 Curative liver resection NA NA 0.82 (0.64–1.06) NA
Petrick et al. (2015)20 America RC 1985–2010 477470/606663 368/313 NA NA 0.68 (0.57–0.81) NA NA
Li et al. (2016)42 Chinese (Mainland) RC 01/2008-12/2013 60/60 60/60 unresectable HCC treatment of cardiovascular disease, transient ischemic attack, and arthritis NA NA 0.498 (0.28–0.888)
Yang et al. (2016)22 Britain RCC 1988–2011 1670/4165 376/819 NA NA 1.11 (0.86–1.44) NA NA
Hwang et al. (2018)19 Korea RC 01/2007-12/2013 64782/395973 382/1954 NA NA 0.87 (0.77–0.98) NA NA
Simon et al. (2018)36 America PC 1980–2012 58855/74516 NA NA Headache, musculoskeletal pain and primary cardiovascular disease prevention (NHS), and cardiovascular disease risk reduction, pain, and headache (HPFS) 0.51 (0.34–0.77) NA NA
Du et al. (2019)40 Chinese (Mainland) RC 01/2000-12/2014 59/205 NA HBV, HCV, cirrhotic, after splenectomy Postoperative long-term low-dose aspirin administration 0.16 (0.04–0.88) NA 0.281 (0.049–0.96)
Lee et al. (2019)34 Taiwan RC 01/1997-12/2012 2123/8492 NA HBV antiplatelet therapy for cardiovascular diseases 0.71 (0.58–0.86) NA NA
Tsoi et al. (2019)35 Chinese (Mainland) RC 2000–2013 204170/408339 1984/7386 NA to prevent cardiovascular and cerebrovascular diseases 0.49 (0.45–0.53) NA NA
Young et al. (2019)43 Taiwan RC 10/2007-05/2014 15/415 15/32 HBV, curative resection of HCC coronary artery disease, type 2 diabetes mellitus or before the surgery of HCC NA 0.221 (0.054–0.915) 0.582 (0.143–2.365)
Liao et al. (2020)37 Taiwan RC 2000–2012 1911/1911 131/147 HCV treated with aspirin 0.56 (0.43–0.72) NA NA
Shen et al. (2020)24 America RCC 01/2011-02/2016 676/1129 186/466 NA NA 0.39 (0.30–0.52) NA NA
Shin et al. (2020)38 Korea RC 08/2003-05/2016 224/725 NA alcoholic cirrhosis aspirin therapy 0.14 (0.09–0.22) NA NA
Simon et al. (2020)39 Sweden RCC 07/2005-12/2013 14205/36070 338/1274 HBV, HCV cardiovascular prevention 0.69 (0.62–0.76) NA 0.73 (0.67–0.81)
Open in a new tab

PC, prospective cohort; RC, retrospective cohort; RCC, retrospective case-control; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; CI, confidence interval; NA, not available.

TABLE 2.

Definition of aspirin user, aspirin dose and adjusted variables.

Study Definition of aspirin user Aspirin dose Adjusted variables
Jacobs et al. (2012)41 Use 30 or 31 days per month of either low-dose or adult-strength aspirin Low-dose or adult-dose aspirin Age, sex, race, education, smoking, history of heart disease, stroke, diabetes, hypertension, cholesterol-lowering drug use (current), aspirin use in the year 1982, nonsteroidal anti-inflammatory drug use, and history of colorectal endoscopy (ever)
Sahasrabuddhe et al. (2012)21 Self-reported aspirin use Monthly (≤2–3 times per month), weekly (1–2 times to 5–6 times per week), or daily use (≥1 times per day) Age, sex, race, cigarette smoking, alcohol consumption, diabetes, and body mass index
Yeh et al. (2014)44 Retrieved from the pharmacy register data set NA Age, sex, extent of liver resection, chronic viral hepatitis status, comorbidities, and the use of drugs such as statin and metformin
Petrick et al. (2015)20 Get from ten US-based prospective cohort studies NA Age, sex, race, cohort, body mass index, smoking, drinking, diabetes
Li et al. (2016)42 Administered at least 100 mg/day of aspirin continuously for more than 3 months ≥100 mg/day Age, gender, date of HCC diagnosis, Child-Pugh score, following treatment after the initial TACE, tumor size, tumor number, vascular invasion, and metastasis the initial date of HCC diagnosis
Yang et al. (2016)22 Having two or more aspirin prescriptions recorded prior to the index date of the individual NA Body mass index, smoking status, alcohol-related disorders, hepatitis B or C virus infection, diabetes, rare metabolic disorders, and use of paracetamol, antidiabetic medications, and statins
Hwang et al. (2018)19 Used more than 365 DDDs of aspirin ≥365 DDDs Age, sex, body mass index, health behaviors (cigarette smoking, alcohol consumption, and physical activity), concurrent medication, category of blood pressure, fasting plasma glucose and total cholesterol, socioeconomic status, and Charlson comorbidity index score
Simon et al. (2018)36 ≥standard-dose [325-mg] tablets per week ≥325 mg/week Body mass index, alcohol intake, smoking status, physical activity, diabetes, hypertension, dyslipidemia, Regular multivitamin use, regular use of oral antidiabetic medications, regular use of statins, regular use of non-aspirin nonsteroidal anti-inflammatory drugs
Du et al. (2019)40 Taking 100 mg/d aspirin within 7 days 100 mg/d Gender, AST, INR, surgical method, postoperative early aspirin
Lee et al. (2019)34 Received daily aspirin for 90 or more days ≤100 mg/d Age, male sex, liver cirrhosis, diabetes, hyperlipidemia, hypertension, statin use, metformin use, and Nucleoside analogues use
Tsoi et al. (2019)35 Adults with aspirin prescription for at least 6 months The median dose of aspirin was 80 mg Age, sex
Young et al. (2019)43 Continuous use of aspirin for at least 30 days before tumor recurrence NA Age, sex, and other covariates
Liao et al. (2020)37 NA NA Age, sex, comorbidities, drugs, diagnosis year, and index year
Shen et al. (2020)24 At least once per week over a duration of 3 months or more NA Age, gender, race, education, household income, and marital status
Shin et al. (2020)38 Who were treated with aspirin more than 6 months 100 mg/day NA
Simon et al. (2020)39 Identified by their first filled prescriptions for 90 or more consecutive doses of aspirin Low-dose aspirin (≤160 mg) Sex; continuous years since diagnosis of hepatitis B or hepatitis C; liver disease severity, hypertension, obesity, or alcohol abuse or misuse; and use of insulin, metformin, and statins, and so on
Open in a new tab

US, United States; HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; INR, international normalized ratio; DDD, defined daily dose; NA, not available.

2.4 Assessment of Risk of Bias

We included thirteen cohort studies and three case-control studies in this meta-analysis. The Newcastle Ottawa scale (NOS) was used to assess the risk of bias for each outcome in all included studies ((BS et al., 2021)). According to the study population selection, comparability, and adequacy of the outcome data, a total of nine points were obtained articles with seven to nine points are considered high-quality articles ((Yang et al., 2016; Shen et al., 2020)) Publication bias was assessed for the primary outcome only. The result of the NOS was shown in Supplementary Table S3.

2.5 Primary and Secondary Outcomes

The main study outcome of this meta-analysis was incidence of HCC, and the secondary outcomes were recurrence and mortality of HCC.

2.6 Statistical Analysis

Heterogeneity between articles was presented as HRs and 95% CIs, and were determined using a random or fixed effect model. Heterogeneity was further assessed by Chi2 and I 2 test, in which the percentage of variability was determined (not sampling error) (Higgins and Thompson 2002; Higgins et al., 2003). Articles with p values <0.10 or I 2 value >50% was considered having substantial heterogeneity. If there is heterogeneity, subgroup analysis will be conducted to explore the potential sources of heterogeneity and consider whether the random effects model can be used for meta-analysis. In addition, Begg funnel plot and Egger’s linear regression were used to evaluate the potential publication bias of the main results of the included studies ((Begg and Mazumdar 1994; Stuck et al., 1998)). Dissymmetry was evaluated visually by Funnel plots. For Egger’s tests, p < 0.1 indicated a significantly small study size. The robustness of the results for primary outcome was evaluated by one-way sensitivity analysis. All statistical analyses were conducted using STATA 14.0 (College Station, Texas 77845 United States, Serial number: 401406267051). Differences for which p < 0.05 (two-sided) were considered statistically significant.

3 Results

3.1 Included Studies

A total of 915 relevant articles were searched, among which 191 articles were duplicates and were removed. After the initial search, 64 articles that discuss problems related to the main goal of this study were selected. Finally, 16 articles ((Sahasrabuddhe et al., 2012; Petrick et al., 2015; Yang et al., 2016; Hwang et al., 2018), (Sahasrabuddhe et al., 2012; Petrick et al., 2015; Yang et al., 2016; Hwang et al., 2018), (Jacobs et al., 2012; Yeh et al., 2015; Li et al., 2016; Simon et al., 2018; Du et al., 2019; Lee et al., 2019; Tsoi et al., 2019; Liao et al., 2020; Shin et al., 2020; Simon et al., 2020; Young et al., 2020)), in which 2781100 patients were involved, and selected (Figure 1).

FIGURE 1.

FIGURE 1

Open in a new tab

Workflow for database search used in the meta-analysis.

3.2 Characteristics of Included Studies

The included articles were observational studies that reported the relationship between aspirin and HCC. Among which, twelve articles reported the relationship between aspirin and incidence of HCC((Sahasrabuddhe et al., 2012; Petrick et al., 2015; Yang et al., 2016; Hwang et al., 2018), (Sahasrabuddhe et al., 2012; Petrick et al., 2015; Yang et al., 2016; Hwang et al., 2018), (Simon et al., 2018; Du et al., 2019; Lee et al., 2019; Tsoi et al., 2019; Liao et al., 2020; Shin et al., 2020; Simon et al., 2020)), two articles showed the relation between aspirin and recurrence of HCC((Yeh et al., 2015; Young et al., 2020)), and five articles indicated the connection between aspirin and mortality of HCC((Jacobs et al., 2012; Li et al., 2016; Du et al., 2019; Simon et al., 2020; Young et al., 2020)). All the included articles gained NOS of greater than or equal to 7 points, suggesting that there is a low risk of bias. The characteristics of the included articles are shown as Table 1 and Table 2.

3.3 Primary and Secondary Outcome

A random-effects model was used to perform in this meta-analysis for incidence and recurrence due to substantial heterogeneity (I 2 = 92.5%, 68.7%, respectively), and fixed-effects model was used to perform in this meta-analysis for mortality due to mild heterogeneity (I 2 = 26.4%) between studies. The pooled results from these studies showed that aspirin is associated with lower incidence of HCC (HR, 0.56; 95% CI, 0.46-0.69, p < 0.001; I 2 = 92.5%; Figure 2). These articles suggest that aspirin is associated with a lower risk of HCC mortality (HR, 0.71; 95% CI, 0.65-0.78; p < 0.001; I 2 = 26.4%; Figure 3), not HCC recurrence (HR, 0.52; 95% CI, 0.15-1.76; p = 0.291; I 2 = 68.7%; Figure 4).

FIGURE 2.

FIGURE 2

Open in a new tab

Meta-analysis of overall pooled HRs with 95% CIs across studies for primary outcomes. Forest plot showing the significance of the relationship between aspirin use and incidence risk of HCC according to the random-effects model.

FIGURE 3.

FIGURE 3

Open in a new tab

Meta-analysis of overall pooled HRs with 95% CIs across studies for secondary outcomes. Forest plot showing the significance of the relationship between aspirin use and mortality of HCC according to the fixed-effects model.

FIGURE 4.

FIGURE 4

Open in a new tab

Meta-analysis of overall pooled HRs with 95% CIs across studies for secondary outcomes. Forest plot showing the significance of the relationship between aspirin use and recurrence of HCC according to the random-effects model.

3.4 Subgroup Analysis

Subgroup analysis further showed that use of aspirin is linked to a lower incidence of HCC in patients with alcoholic cirrhosis (HR, 0.14; 95% CI, 0.09-0.22; p < 0.001; I 2 = 0%; Figure 5), virus hepatitis (HR, 0.68; 95% CI, 0.62-0.74; p < 0.001; I 2 = 48.1%; Figure 6). Obviously, aspirin is associated with a lower incidence rate of liver cancer in alcoholic cirrhosis.

FIGURE 5.

FIGURE 5

Open in a new tab

Meta-analysis of overall pooled HRs with 95% CIs across studies for primary outcomes in subgroup analyses. Forest plot showing the significance of the relationship between aspirin use and incidence risk of HCC in alcoholic cirrhosis patients according to the fixed-effects model.

FIGURE 6.

FIGURE 6

Open in a new tab

Meta-analysis of overall pooled HRs with 95% CIs across studies for primary outcomes in subgroup analyses. Forest plot showing the significance of the relationship between aspirin use and incidence risk of HCC in virus hepatitis patients according to the fixed-effects model.

3.5 Sensitivity Analyses

Since the included studies were observational studies, the risk of bias was low (Supplementary Table S3), we did not conduct a sensitivity analysis of the methodological criteria. So we conduct a sensitivity analysis to evaluate the effect of any one study on the pooled HRs and 95% CIs by removing one individual study at a time. The results showed that the meta-analysis is robust and reliable (Supplementary Figure S1).

3.6 Publication Bias

We employed the funnel plots (Supplementary Figure S2) and the egger’s regression asymmetry tests (Supplementary Figure S3) to evaluate potential publication bias of the included studies. We observed a slight asymmetry in the funnel plots and the Egger’s Publication bias plot. However the results of Egger’s regression asymmetry tests confirmed no publication bias exist in these studies (p = 0.594).

4 Discussion

Evaluation of studies that enrolled 2781100 participants demonstrated that the incidence of HCC was lower in patients with alcoholic cirrhosis and virus hepatitis who use aspirin than that of patients who do not use aspirin, but also the mortality of HCC was lower in aspirin users than those in non-aspirin users. This finding suggests that the use of aspirin was associated with decreased risk of HCC and the risk of HCC mortality. However, clinical trials should be further conducted to confirm this suggestion.

Aspirin is a first-line nonsteroidal anti-inflammatory drug (NSAID), which has been reported to have chemo-protective effects, according to epidemiological researches. Studies ((Gann et al., 1993; Cook et al., 2005; Flossmann and Rothwell 2007; Burn et al., 2011)), in which patients with different genders and are from different regions were enrolled, have indicated the association between aspirin and cancer risk. While some recent studies have reported that NSAID ((Sahasrabuddhe et al., 2012; Petrick et al., 2015)), especially for aspirin, may be able to protect against incidence risk of HCC, other studies have indicated that non-aspirin NSAID could also reduce the number of HCC incidence ((Pang et al., 2017; Tao et al., 2018)). Thus, to further clarify this, we evaluated several studies ((Pang et al., 2017; Tao et al., 2018), (Simon et al., 2018; Liao et al., 2020; Shin et al., 2020), (Oh et al., 2017)), in which aspirin users and non-aspirin users were compared. Our investigation suggested that aspirin was associated with a reduced risk of HCC. And the subgroup analysis result of our meta-analysis also indicated that aspirin use was associated with a reduced incidence of HCC in virus hepatitis and alcoholic cirrhosis patients. Similar effects or mechanisms have also been observed in chronic hepatitis patients ((Maini and Schurich 2012; Sitia et al., 2013)). The presence of hepatitis virus causes CD8+ lymphocytes to secret many inflammatory factors involving in the dealing with infection; inability to timely clear the virus can lead to failure of the liver. Although numerous articles have demonstrated that aspirin users has a significantly lower incidence of HCC compared with non-aspirin users ((Maini and Schurich 2012; Sitia et al., 2013), (Maini and Schurich 2012; Sitia et al., 2013), (Maini and Schurich 2012; Sitia et al., 2013), (Maini and Schurich 2012; Sitia et al., 2013), (Simon et al., 2019), (Lee et al., 2017)), contradictory results have been reported by some studies ((Chiu et al., 2011; Kim et al., 2017), (Chiu et al., 2011; Kim et al., 2017)). Moreover, a meta-analysis that included 5 studies for incidence and 2 studies for mortality reported aspirin use could reduce the incidence risk of HCC((Chiu et al., 2011; Kim et al., 2017)), and also the 2-years and 4-years mortalities in patients with HCC. And the result is consistent with our meta-analysis. However another meta-analysis that included 5 studies reported aspirin use could not reduce the incidence risk of HCC((Chiu et al., 2011; Kim et al., 2017)). In addition, A recent meta-analysis included 8 cohort studies by Wang et al. focused on the dose-response effect of aspirin use and incidence risk of HCC((Chiu et al., 2011; Kim et al., 2017)), and which reported that the higher the aspirin dose, the lower incidence risk of HCC. However, all these three previous meta-analysis may lead to the in-reliable result as their small number of included studies ((Pang et al., 2017; Tao et al., 2018; Wang et al., 2020)). Besides, we also look forward to more studies on the dose dependence or time dependence between aspirin and HCC occur. In all, the majority of evidences shown above indicate that use of aspirin could reduce the incidence risk of HCC, also aspirin use and lower mortality in HCC patients.

Several mechanisms may support the beneficial effects of aspirin on the incidence risk of HCC. Aspirin has a very short half-life in the serum; it selectively inhibits the platelet COX-1. Patients with inflammation-related cancer, including HCC, have increased levels of pro-inflammatory factor, COX-2 enzyme ((Lim et al., 2000; Yip-Schneider et al., 2000; Singh et al., 2005; Chan et al., 2007)). Animal studies have suggested that aspirin at high doses is required to completely inhibit COX-2 ((Kern et al., 2002; Foderà et al., 2004; Chen et al., 2017)). Additionally, higher COX-2 levels can induce the hepatocarcinogenesis-related inflammatory factor cascades, such as protein kinase 3 (PK-3) and nuclear factor κB (NF-κB) pathways ((Iannacone et al., 2005)). Aspirin at high doses could block the NF-κB and PK-3 pathways ((Chan et al., 1998; Leng et al., 2003; Patrono et al., 2005)). The mechanisms in which use of aspirin may benefit HCC patients with HBV are as follows: while platelets accelerate HBV-related liver injury by retaining inflammation (69), aspirin exerts its anti-inflammation by inhibiting the production of thromboxane A2 and relevant platelet activation pathways ((Cattaneo 2004; Aiolfi and Sitia 2015)). Moreover, the use of aspirin antiplatelet therapy reduces the frequency of platelet immune cell interaction and intrahepatic platelet accumulation, thereby limiting the transport of hepatic immune cells, which can prevent the development of non-alcoholic steatohepatitis (NASH) and subsequent HCC((Malehmir et al., 2019)). Other studies have suggested that anti-platelet therapy can diminish not only the intrahepatic HBV-specific CD8 T cells ((Cattaneo 2004; Aiolfi and Sitia 2015)), but also normal inflammatory cells; as a result, HCC is developing in the construction of HBV transgenic animal model. A study of a xenograft nude mouse model have also indicated that use of aspirin could inhibit growth and/or death of HCC tumor ((Cattaneo 2004; Aiolfi and Sitia 2015), (Li et al., 2013b)).

This study has several advantages. First, the total sample sizes are sufficient for this meta-analysis; therefore, the bias from sample sizes can be diminished; Second, it is the first systematic review and meta-analysis to analyses the incidence of HCC in aspirin users in patients with virus hepatitis and alcoholic cirrhosis. Third, the results shown in the NOS quality list showed that this article may have a risk of bias, suggesting the methodology used in the original studies has higher quality; Moreover, the outcome data in the included studies were adjusted into the primary and secondary outcomes; hence, analyses of effects of aspirin on the incidence, and recurrence and mortality of HCC were conducted separately. Furthermore, the synthetic HR and its 95% CI were obtained using the generic inverse variance methods of random-effect models; thus, the obtained HR indicates the sum effect of aspirin on HCC incidence. More importantly, although all the included studies are observational studies, the main confounding variables that impacted the primary results that were adjusted in most of original articles. Finally the sensitivity analysis results suggested that the meta-analysis employed in this study is robust and reliable.

Despite the above strengths, this study has some limitation: First, high heterogeneity was observed in the sum effect of aspirin on the incidence of HCC, suggesting the results presented here may be different from those in the original articles (NOS assessment, however, indicated that the conclusions presented here is reliable); Second, aspirin dose and period of use were varied in the original studies, which may affect the results shown in this study and may be the source of heterogeneity; therefore, further researches are needed; Third, the small included studies for aspirin use and incidence of HCC in alcoholic cirrhosis patients may lead to the in-reliable result. However, it is clear that use of aspirin has a significant reduction in the incidence of HCC in patients with alcoholic cirrhosis and virus hepatitis. Fourth, this study evaluate only the preventive or therapeutic effect of aspirin on HCC patients, not its safety, administration initiation or continuation; Finally, more importantly, although the included articles have a low risk of bias, this study did not include randomized controlled trials, which may be one of the most important disadvantages.

This article presents the first meta-analysis that elaborate on the beneficial effect of aspirin on HCC incidence in patients with or without virus hepatitis and alcoholic cirrhosis. The analysis indicated that aspirin could decrease the incidence risk of HCC including virus hepatitis, especially for patients with alcoholic cirrhosis, and also the mortality of HCC. However, further clinical trials are encouraged to be conducted to support the present results.

Acknowledgments

We would like to thank Chinese Evidence Based Medicine Center, West China Hospital, Sichuan University provided the Stata 14.0 statistical software.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author Contributions

Conceptualization, ZF and LL; Data curation, XZ; Formal analysis, XZ; Funding acquisition, ZF and LL; Investigation, LM and YS; Methodology, YS and CL; Project administration, XZ and YS; Software, YZ and LM; Validation, LL; Visualization, LM; Writing–original draft, XD and YZ; Writing–review and editing, XZ.

Funding

This study was supported by the Special Project of Traditional Chinese Medicine Research in Henan Province (Grant No. 20-21ZY2311), Henan Province Medical Science and Technology Research Project Joint Construction Project (Grant No. LHGJ20190003, LHGJ20190055), Young and Middle-aged Health Science and Technology Innovation Talents in 2020 (Grant No. YXKC2020049), and Key scientific research projects of higher education institutions in Henan Province (Grant No. 21A320036).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.764854/full#supplementary-material

Click here for additional data file. (262.2KB, TIF)
Click here for additional data file. (152.5KB, doc)
Click here for additional data file. (314.5KB, TIF)
Click here for additional data file. (417.2KB, TIF)
Click here for additional data file. (61.5KB, doc)
Click here for additional data file. (16.7KB, docx)

References

  1. Aiolfi R., Sitia G. (2015). Chronic Hepatitis B: Role of Anti-platelet Therapy in Inflammation Control. Cell Mol Immunol 12 (3), 264–268. 10.1038/cmi.2014.124 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Akinyemiju T., Akinyemiju T., Abera S., Ahmed M., Alam N., Alemayohu M. A., et al. (2017). The Burden of Primary Liver Cancer and Underlying Etiologies from 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015. JAMA Oncol. 3 (12), 1683–1691. 10.1001/jamaoncol.2017.3055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Altekruse S. F., McGlynn K. A., Dickie L. A., Kleiner D. E. (2012). Hepatocellular Carcinoma Confirmation, Treatment, and Survival in Surveillance, Epidemiology, and End Results Registries, 1992-2008. Hepatology 55 (2), 476–482. 10.1002/hep.24710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Begg C. B., Mazumdar M. (1994). Operating Characteristics of a Rank Correlation Test for Publication Bias. Biometrics 50 (4), 1088–1101. 10.2307/2533446 [DOI] [PubMed] [Google Scholar]
  5. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 68 (6), 394–424. 10.3322/caac.21492 [DOI] [PubMed] [Google Scholar]
  6. Bs G. W., O’Connell D., Robertson J., Peterson J., Welch V., Losos M., et al. (2021).The Newcastle-Ottawa Scale (NOS) for Assesing the Quality of Nonrandomized Studies in Meta-Analysis. (Accessed November 18, 2019). [Google Scholar]
  7. Burn J., Gerdes A. M., Macrae F., Mecklin J. P., Moeslein G., Olschwang S., et al. (2011). Long-term Effect of Aspirin on Cancer Risk in Carriers of Hereditary Colorectal Cancer: an Analysis from the CAPP2 Randomised Controlled Trial. Lancet 378 (9809), 2081–2087. 10.1016/s0140-6736(11)61049-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cao Y., Nishihara R., Wu K., Wang M., Ogino S., Willett W. C., et al. (2016). Population-wide Impact of Long-Term Use of Aspirin and the Risk for Cancer. JAMA Oncol. 2 (6), 762–769. 10.1001/jamaoncol.2015.6396 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Carrat F. (2014). Statin and Aspirin for Prevention of Hepatocellular Carcinoma: what Are the Levels of Evidence? Clin. Res. Hepatol. Gastroenterol. 38 (1), 9–11. 10.1016/j.clinre.2013.09.007 [DOI] [PubMed] [Google Scholar]
  10. Cattaneo M. (2004). Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance. Arterioscler Thromb. Vasc. Biol. 24 (11), 1980–1987. 10.1161/01.ATV.0000145980.39477.a9 [DOI] [PubMed] [Google Scholar]
  11. Chan A. T., Ogino S., Fuchs C. S. (2007). Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. N. Engl. J. Med. 356 (21), 2131–2142. 10.1056/NEJMoa067208 [DOI] [PubMed] [Google Scholar]
  12. Chan T. A., Morin P. J., Vogelstein B., Kinzler K. W. (1998). Mechanisms Underlying Nonsteroidal Antiinflammatory Drug-Mediated Apoptosis. Proc. Natl. Acad. Sci. U S A. 95 (2), 681–686. 10.1073/pnas.95.2.681 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Chen C. J., Liang K. Y., Chang A. S., Chang Y. C., Lu S. N., Liaw Y. F., et al. (1991). Effects of Hepatitis B Virus, Alcohol Drinking, Cigarette Smoking and Familial Tendency on Hepatocellular Carcinoma. Hepatology 13 (3), 398–406. 10.1002/hep.1840130303 [DOI] [PubMed] [Google Scholar]
  14. Chen H., Cai W., Chu E. S. H., Tang J., Wong C. C., Wong S. H., et al. (2017). Hepatic Cyclooxygenase-2 Overexpression Induced Spontaneous Hepatocellular Carcinoma Formation in Mice. Oncogene 36 (31), 4415–4426. 10.1038/onc.2017.73 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cheng A. S., Chan H. L., Leung W. K., To K. F., Go M. Y., Chan J. Y., et al. (2004). Expression of HBx and COX-2 in Chronic Hepatitis B, Cirrhosis and Hepatocellular Carcinoma: Implication of HBx in Upregulation of COX-2. Mod. Pathol. 17 (10), 1169–1179. 10.1038/modpathol.3800196 [DOI] [PubMed] [Google Scholar]
  16. Chiu H. F., Ho S. C., Chen C. C., Yang C. Y. (2011). Statin Use and the Risk of Liver Cancer: a Population-Based Case–Control Study. Am. J. Gastroenterol. 106 (5), 894–898. 10.1038/ajg.2010.475 [DOI] [PubMed] [Google Scholar]
  17. Cook N. R., Lee I. M., Gaziano J. M., Gordon D., Ridker P. M., Manson J. E., et al. (2005). Low-dose Aspirin in the Primary Prevention of Cancer: the Women's Health Study: a Randomized Controlled Trial. Jama 294 (1), 47–55. 10.1001/jama.294.1.47 [DOI] [PubMed] [Google Scholar]
  18. Degos F., Christidis C., Ganne-Carrie N., Farmachidi J. P., Degott C., Guettier C., et al. (2000). Hepatitis C Virus Related Cirrhosis: Time to Occurrence of Hepatocellular Carcinoma and Death. Gut 47 (1), 131–136. 10.1136/gut.47.1.131 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Du Z. Q., Zhao J. Z., Dong J., Bi J. B., Ren Y. F., Zhang J., et al. (2019). Effect of Low-Dose Aspirin Administration on Long-Term Survival of Cirrhotic Patients after Splenectomy: A Retrospective Single-center Study. World J. Gastroenterol. 25 (28), 3798–3807. 10.3748/wjg.v25.i28.3798 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Flossmann E., Rothwell P. M. (2007). Effect of Aspirin on Long-Term Risk of Colorectal Cancer: Consistent Evidence from Randomised and Observational Studies. Lancet 369 (9573), 1603–1613. 10.1016/s0140-6736(07)60747-8 [DOI] [PubMed] [Google Scholar]
  21. Foderà D., D'Alessandro N., Cusimano A., Poma P., Notarbartolo M., Lampiasi N., et al. (2004). Induction of Apoptosis and Inhibition of Cell Growth in Human Hepatocellular Carcinoma Cells by COX-2 Inhibitors. Ann. N. Y Acad. Sci. 1028, 440–449. 10.1196/annals.1322.052 [DOI] [PubMed] [Google Scholar]
  22. Gann P. H., Manson J. E., Glynn R. J., Buring J. E., Hennekens C. H. (1993). Low-dose Aspirin and Incidence of Colorectal Tumors in a Randomized Trial. J. Natl. Cancer Inst. 85 (15), 1220–1224. 10.1093/jnci/85.15.1220 [DOI] [PubMed] [Google Scholar]
  23. Grant R. L. (2014). Converting an Odds Ratio to a Range of Plausible Relative Risks for Better Communication of Research Findings. BMJ 348, f7450. 10.1136/bmj.f7450 [DOI] [PubMed] [Google Scholar]
  24. Greenland S. (1987). Quantitative Methods in the Review of Epidemiologic Literature. Epidemiol. Rev. 9, 1–30. 10.1093/oxfordjournals.epirev.a036298 [DOI] [PubMed] [Google Scholar]
  25. Higgins J. P., Thompson S. G., Deeks J. J., Altman D. G. (2003). Measuring Inconsistency in Meta-Analyses. BMJ 327 (7414), 557–560. 10.1136/bmj.327.7414.557 [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Higgins J. P., Thompson S. G. (2002). Quantifying Heterogeneity in a Meta-Analysis. Stat. Med. 21 (11), 1539–1558. 10.1002/sim.1186 [DOI] [PubMed] [Google Scholar]
  27. Hossain M. A., Kim D. H., Jang J. Y., Kang Y. J., Yoon J. H., Moon J. O., et al. (2012). Aspirin Induces Apoptosis In Vitro and Inhibits Tumor Growth of Human Hepatocellular Carcinoma Cells in a Nude Mouse Xenograft Model. Int. J. Oncol. 40 (4), 1298–1304. 10.3892/ijo.2011.1304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Hwang I. C., Chang J., Kim K., Park S. M. (2018). Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. Sci. Rep. 8 (1), 4968. 10.1038/s41598-018-23343-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Iannacone M., Sitia G., Isogawa M., Marchese P., Castro M. G., Lowenstein P. R., et al. (2005). Platelets Mediate Cytotoxic T Lymphocyte-Induced Liver Damage. Nat. Med. 11 (11), 1167–1169. 10.1038/nm1317 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Jacobs E. J., Newton C. C., Gapstur S. M., Thun M. J. (2012). Daily Aspirin Use and Cancer Mortality in a Large US Cohort. J. Natl. Cancer Inst. 104 (16), 1208–1217. 10.1093/jnci/djs318 [DOI] [PubMed] [Google Scholar]
  31. Kern M. A., Schubert D., Sahi D., Schöneweiss M. M., Moll I., Haugg A. M., et al. (2002). Proapoptotic and Antiproliferative Potential of Selective Cyclooxygenase-2 Inhibitors in Human Liver Tumor Cells. Hepatology 36 (4 Pt 1), 885–894. 10.1053/jhep.2002.36125 [DOI] [PubMed] [Google Scholar]
  32. Kim G., Jang S. Y., Han E., Lee Y. H., Park S. Y., Nam C. M., et al. (2017). Effect of Statin on Hepatocellular Carcinoma in Patients with Type 2 Diabetes: A Nationwide Nested Case-Control Study. Int. J. Cancer 140 (4), 798–806. 10.1002/ijc.30506 [DOI] [PubMed] [Google Scholar]
  33. Lapi F., Levi M., Simonetti M., Cancian M., Parretti D., Cricelli I., et al. (2016). Risk of Prostate Cancer in Low-Dose Aspirin Users: A Retrospective Cohort Study. Int. J. Cancer 139 (1), 205–211. 10.1002/ijc.30061 [DOI] [PubMed] [Google Scholar]
  34. Lee M., Chung G. E., Lee J. H., Oh S., Nam J. Y., Chang Y., et al. (2017). Antiplatelet Therapy and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Antiviral Treatment. Hepatology 66 (5), 1556–1569. 10.1002/hep.29318 [DOI] [PubMed] [Google Scholar]
  35. Lee T. Y., Hsu Y. C., Tseng H. C., Yu S. H., Lin J. T., Wu M. S., et al. (2019). Association of Daily Aspirin Therapy with Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. JAMA Intern. Med. 179 (5), 633–640. 10.1001/jamainternmed.2018.8342 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Leng J., Han C., Demetris A. J., Michalopoulos G. K., Wu T. (2003). Cyclooxygenase-2 Promotes Hepatocellular Carcinoma Cell Growth through Akt Activation: Evidence for Akt Inhibition in Celecoxib-Induced Apoptosis. Hepatology 38 (3), 756–768. 10.1053/jhep.2003.50380 [DOI] [PubMed] [Google Scholar]
  37. Li G., Zhang S., Fang H., Yan B., Zhao Y., Feng L., et al. (2013). Aspirin Overcomes Navitoclax-Resistance in Hepatocellular Carcinoma Cells through Suppression of Mcl-1. Biochem. Biophys. Res. Commun. 434 (4), 809–814. 10.1016/j.bbrc.2013.04.018 [DOI] [PubMed] [Google Scholar]
  38. Li J. H., Wang Y., Xie X. Y., Yin X., Zhang L., Chen R. X., et al. (2016). Aspirin in Combination with TACE in Treatment of Unresectable HCC: a Matched-Pairs Analysis. Am. J. Cancer Res. 6 (9), 2109–2116. [PMC free article] [PubMed] [Google Scholar]
  39. Li T., Dong Z. R., Guo Z. Y., Wang C. H., Tang Z. Y., Qu S. F., et al. (2013). Aspirin Enhances IFN-α-Induced Growth Inhibition and Apoptosis of Hepatocellular Carcinoma via JAK1/STAT1 Pathway. Cancer Gene Ther. 20 (6), 366–374. 10.1038/cgt.2013.29 [DOI] [PubMed] [Google Scholar]
  40. Liao Y. H., Hsu R. J., Wang T. H., Wu C. T., Huang S. Y., Hsu C. Y., et al. (2020). Aspirin Decreases Hepatocellular Carcinoma Risk in Hepatitis C Virus Carriers: a Nationwide Cohort Study. BMC Gastroenterol. 20 (1), 6. 10.1186/s12876-020-1158-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lim H. Y., Joo H. J., Choi J. H., Yi J. W., Yang M. S., Cho D. Y., et al. (2000). Increased Expression of Cyclooxygenase-2 Protein in Human Gastric Carcinoma. Clin. Cancer Res. 6 (2), 519–525. [PubMed] [Google Scholar]
  42. Maini M. K., Schurich A. (2012). Platelets Harness the Immune Response to Drive Liver Cancer. Proc. Natl. Acad. Sci. U S A. 109 (32), 12840–12841. 10.1073/pnas.1210296109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Malehmir M., Pfister D., Gallage S., Szydlowska M., Inverso D., Kotsiliti E., et al. (2019). Platelet GPIbα Is a Mediator and Potential Interventional Target for NASH and Subsequent Liver Cancer. Nat. Med. 25 (4), 641–655. 10.1038/s41591-019-0379-5 [DOI] [PubMed] [Google Scholar]
  44. McGlynn K. A., London W. T. (2011). The Global Epidemiology of Hepatocellular Carcinoma: Present and Future. Clin. Liver Dis. 15 (2), 223–x. 10.1016/j.cld.2011.03.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Oh S., Shin S., Lee S. H., Kim T. S., Nam S.-J., Park J. M., et al. (2017). Aspirin and the Risk of Hepatocellular Carcinoma Development in Patients with Compensated Alcoholic Cirrhosis. J. Hepatol. 66 (1), S629–S630. 10.1016/s0168-8278(17)31706-3 [DOI] [Google Scholar]
  46. Pang Q., Jin H., Qu K., Man Z., Wang Y., Yang S., et al. (2017). The Effects of Nonsteroidal Anti-inflammatory Drugs in the Incident and Recurrent Risk of Hepatocellular Carcinoma: a Meta-Analysis. Onco Targets Ther. 10, 4645–4656. 10.2147/ott.s143154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Patrono C., García Rodríguez L. A., Landolfi R., Baigent C. (2005). Low-dose Aspirin for the Prevention of Atherothrombosis. N. Engl. J. Med. 353 (22), 2373–2383. 10.1056/NEJMra052717 [DOI] [PubMed] [Google Scholar]
  48. Petrick J. L., Sahasrabuddhe V. V., Chan A. T., Alavanja M. C., Beane-Freeman L. E., Buring J. E., et al. (2015). NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Prev. Res. (Phila) 8 (12), 1156–1162. 10.1158/1940-6207.capr-15-0126 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Raza H., John A., Benedict S. (2011). Acetylsalicylic Acid-Induced Oxidative Stress, Cell Cycle Arrest, Apoptosis and Mitochondrial Dysfunction in Human Hepatoma HepG2 Cells. Eur. J. Pharmacol. 668 (1-2), 15–24. 10.1016/j.ejphar.2011.06.016 [DOI] [PubMed] [Google Scholar]
  50. Sahasrabuddhe V. V., Gunja M. Z., Graubard B. I., Trabert B., Schwartz L. M., Park Y., et al. (2012). Nonsteroidal Anti-inflammatory Drug Use, Chronic Liver Disease, and Hepatocellular Carcinoma. J. Natl. Cancer Inst. 104 (23), 1808–1814. 10.1093/jnci/djs452 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Semple J. W., Italiano J. E., Jr., Freedman J. (2011). Platelets and the Immune Continuum. Nat. Rev. Immunol. 11 (4), 264–274. 10.1038/nri2956 [DOI] [PubMed] [Google Scholar]
  52. Shen Y., Risch H., Lu L., Ma X., Irwin M. L., Lim J. K., et al. (2020). Risk Factors for Hepatocellular Carcinoma (HCC) in the Northeast of the United States: Results of a Case-Control Study. Cancer Causes Control 31 (4), 321–332. 10.1007/s10552-020-01277-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Shin S., Lee S. H., Lee M., Kim J. H., Lee W., Lee H. W., et al. (2020). Aspirin and the Risk of Hepatocellular Carcinoma Development in Patients with Alcoholic Cirrhosis. Medicine (Baltimore) 99 (9), e19008. 10.1097/md.0000000000019008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Simon T. G., Duberg A-S., Aleman S., Chung R. T., Ludvigsson J. F. (2019). Aspirin use is Associated with Reduced Risk for Incident Hepatocellular Carcinoma in Patients with Chronic Viral Hepatitis: Results from a Nationwide Population. Gastroenterology 156 (6), S1200. 10.1016/s0016-5085(19)39981-0 [DOI] [Google Scholar]
  55. Simon T. G., Duberg A. S., Aleman S., Chung R. T., Chan A. T., Ludvigsson J. F. (2020). Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N. Engl. J. Med. 382 (11), 1018–1028. 10.1056/NEJMoa1912035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Simon T. G., Ma Y., Ludvigsson J. F., Chong D. Q., Giovannucci E. L., Fuchs C. S., et al. (2018).Association between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol. 4(12), 1683–1690. 10.1001/jamaoncol.2018.4154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Singh B., Berry J. A., Shoher A., Ramakrishnan V., Lucci A. (2005). COX-2 Overexpression Increases Motility and Invasion of Breast Cancer Cells. Int. J. Oncol. 26 (5), 1393–1399. 10.3892/ijo.26.5.1393 [DOI] [PubMed] [Google Scholar]
  58. Siristatidis C., Sergentanis T. N., Kanavidis P., Trivella M., Sotiraki M., Mavromatis I., et al. (2013). Controlled Ovarian Hyperstimulation for IVF: Impact on Ovarian, Endometrial and Cervical Cancer-Aa Systematic Review and Meta-Analysis. Hum. Reprod. Update 19 (2), 105–123. 10.1093/humupd/dms051 [DOI] [PubMed] [Google Scholar]
  59. Sitia G., Aiolfi R., Di Lucia P., Mainetti M., Fiocchi A., Mingozzi F., et al. (2012). Antiplatelet Therapy Prevents Hepatocellular Carcinoma and Improves Survival in a Mouse Model of Chronic Hepatitis B. Proc. Natl. Acad. Sci. U S A. 109 (32), E2165–E2172. 10.1073/pnas.1209182109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Sitia G., Iannacone M., Guidotti L. G. (2013). Anti-platelet Therapy in the Prevention of Hepatitis B Virus-Associated Hepatocellular Carcinoma. J. Hepatol. 59 (5), 1135–1138. 10.1016/j.jhep.2013.05.040 [DOI] [PubMed] [Google Scholar]
  61. Stroup D. F., Berlin J. A., Morton S. C., Olkin I., Williamson G. D., Rennie D., et al. (2000). Meta-analysis of Observational Studies in Epidemiology: a Proposal for Reporting. Meta-Analysis of Observational Studies in Epidemiology (MOOSE) Group. Jama 283 (15), 2008–2012. 10.1001/jama.283.15.2008 [DOI] [PubMed] [Google Scholar]
  62. Stuck A. E., Rubenstein L. Z., Wieland D. (1998). Bias in Meta-Analysis Detected by a Simple, Graphical Test. Asymmetry Detected in Funnel Plot Was Probably Due to True Heterogeneity. BMJ 316 (7129), 469–471. 10.1136/bmj.316.7129.469 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Tao Y., Li Y., Liu X., Deng Q., Yu Y., Yang Z. (2018). Nonsteroidal Anti-inflammatory Drugs, Especially Aspirin, Are Linked to Lower Risk and Better Survival of Hepatocellular Carcinoma: a Meta-Analysis. Cancer Manag. Res. 10, 2695–2709. 10.2147/cmar.s167560 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Torre L. A., Bray F., Siegel R. L., Ferlay J., Lortet-Tieulent J., Jemal A. (2015). Global Cancer Statistics, 2012. CA Cancer J. Clin. 65 (2), 87–108. 10.3322/caac.21262 [DOI] [PubMed] [Google Scholar]
  65. Tsoi K. K. F., Ho J. M. W., Chan F. C. H., Sung J. J. Y. (2019). Long-term Use of Low-Dose Aspirin for Cancer Prevention: A 10-year Population Cohort Study in Hong Kong. Int. J. Cancer 145 (1), 267–273. 10.1002/ijc.32083 [DOI] [PubMed] [Google Scholar]
  66. Villanueva A. (2019). Hepatocellular Carcinoma. N. Engl. J. Med. 380 (15), 1450–1462. 10.1056/NEJMra1713263 [DOI] [PubMed] [Google Scholar]
  67. Wang S., Yu Y., Ryan P. M., Dang M., Clark C., Kontogiannis V., et al. (2020). Association of Aspirin Therapy with Risk of Hepatocellular Carcinoma: A Systematic Review and Dose-Response Analysis of Cohort Studies with 2.5 Million Participants. Pharmacol. Res. 151, 104585. 10.1016/j.phrs.2019.104585 [DOI] [PubMed] [Google Scholar]
  68. Yang B., Petrick J. L., Chen J., Hagberg K. W., Sahasrabuddhe V. V., Graubard B. I., et al. (2016). Associations of NSAID and Paracetamol Use with Risk of Primary Liver Cancer in the Clinical Practice Research Datalink. Cancer Epidemiol. 43, 105–111. 10.1016/j.canep.2016.06.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Ye S., Lee M., Lee D., Ha E. H., Chun E. M. (2019). Association of Long-Term Use of Low-Dose Aspirin as Chemoprevention with Risk of Lung Cancer. JAMA Netw. Open 2 (3), e190185. 10.1001/jamanetworkopen.2019.0185 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Yeh C. C., Lin J. T., Jeng L. B., Ho H. J., Yang H. R., Wu M. S., et al. (2015). Nonsteroidal Anti-inflammatory Drugs Are Associated with Reduced Risk of Early Hepatocellular Carcinoma Recurrence after Curative Liver Resection: a Nationwide Cohort Study. Ann. Surg. 261 (3), 521–526. 10.1097/sla.0000000000000746 [DOI] [PubMed] [Google Scholar]
  71. Yeh M. M., Daniel H. D., Torbenson M. (2010). Hepatitis C-Associated Hepatocellular Carcinomas in Non-cirrhotic Livers. Mod. Pathol. 23 (2), 276–283. 10.1038/modpathol.2009.174 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Yip-Schneider M. T., Barnard D. S., Billings S. D., Cheng L., Heilman D. K., Lin A., et al. (2000). Cyclooxygenase-2 Expression in Human Pancreatic Adenocarcinomas. Carcinogenesis 21 (2), 139–146. 10.1093/carcin/21.2.139 [DOI] [PubMed] [Google Scholar]
  73. Young S. H., Chau G. Y., Lee I. C., Yeh Y. C., Chao Y., Huo T. I., et al. (2020). Aspirin Is Associated with Low Recurrent Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Patients after Curative Resection. J. Formos. Med. Assoc. 119 (1 Pt 2), 218–229. 10.1016/j.jfma.2019.04.018 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (262.2KB, TIF)
Click here for additional data file. (152.5KB, doc)
Click here for additional data file. (314.5KB, TIF)
Click here for additional data file. (417.2KB, TIF)
Click here for additional data file. (61.5KB, doc)
Click here for additional data file. (16.7KB, docx)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES